Rapid Development of Cefiderocol Resistance in Carbapenem-resistant Enterobacter cloacae During Therapy Is Associated With Heterogeneous Mutations in the Catecholate Siderophore Receptor cirA-Reference-Cited by-同舟云学术

Rapid Development of Cefiderocol Resistance in Carbapenem-resistant Enterobacter cloacae During Therapy Is Associated With Heterogeneous Mutations in the Catecholate Siderophore Receptor cirA

Published:2021-06-03 Issue: Volume: Page:
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Klein Sabrina¹,Boutin Sébastien¹,Kocer Kaan¹,Fiedler Mascha O²,Störzinger Dominic³,Weigand Markus A²,Tan Benjamin²,Richter Daniel²,Rupp Christian⁴,Mieth Markus⁵,Mehrabi Arianeb⁵,Hackert Thilo⁵,Zimmermann Stefan¹,Heeg Klaus¹,Nurjadi Dennis¹^ORCID

Affiliation:

1. Department of Infectious Diseases, Medical Microbiology and Hygiene, Heidelberg University Hospital, Heidelberg, Germany

2. Department of Anesthesiology, Heidelberg University Hospital, Heidelberg, Germany

3. Pharmacy Department, Heidelberg University Hospital, Heidelberg, Germany

4. Department of Internal Medicine IV, Heidelberg University Hospital, Heidelberg, Germany

5. Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany

Abstract

Abstract We report a case of resistance development toward cefiderocol in a patient with intra-abdominal and bloodstream infections caused by carbapenemase-producing Enterobacter cloacae within 21 days of cefiderocol therapy. Whole genome sequencing revealed heterogeneous mutations in the cirA gene, encoding a catecholate siderophore receptor, conferring phenotypic resistance to cefiderocol.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciab511/39068577/ciab511.pdf

Reference14 articles.

1. Carbapenem-resistant Enterobacteriaceae in the community: a scoping review;Kelly;Int J Antimicrob Agents,2017

2. Association between carbapenem resistance and mortality among adult, hospitalized patients with serious infections due to enterobacteriaceae: results of a systematic literature review and meta-analysis;Martin;Open Forum Infect Dis,2018

3. Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin;Sato;Clin Infect Dis,2019

4. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria;Ito;Antimicrob Agents Chemother,2018

5. US Food and Drug Administration (FDA): benefit-risk considerations for cefiderocol (Fetroja(R));Naseer;Clin Infect Dis,2020

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vivo emergence of cefiderocol and ceftazidime/avibactam cross-resistance in KPC-producing Klebsiella pneumoniae following ceftazidime/avibactam -based therapies;Diagnostic Microbiology and Infectious Disease;2024-09

2. Survival of infection with TEM β-lactamase-producing Escherichia coli with Pan-β-lactam resistance;Journal of Infection;2024-09

3. In vitro activity of cefiderocol against European Enterobacterales, including isolates resistant to meropenem and recentβ-lactam/β-lactamase inhibitor combinations;Microbiology Spectrum;2024-08-06

4. In vitro resistance development gives insights into molecular resistance mechanisms against cefiderocol;The Journal of Antibiotics;2024-07-30

5. Siderophores: A Case Study in Translational Chemical Biology;Biochemistry;2024-07-23